Recruiting

Observational Study

Sponsor:

Children's Hospital Medical Center, Cincinnati

Code:

NCT03101813

Conditions

Diffuse Intrinsic Pontine Glioma

Diffuse Midline Glioma, H3 K27M-Mutant

Diffuse Midline Glioma

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Doctors and other medical scientists want learn about the biology of DIPG/DMG and to develop better ways to diagnose and treat patients with DIPG/DMG. To do this, they need more information about the characteristics of DIPG/DMG tumors. Therefore, they want to establish a central location for clinical information and tumor tissue collected from DIPG/DMG patients.

The purposes of this study are:

  • To enroll patients diagnosed with DIPG/DMG in the International DIPG/DMG Registry and Repository.
  • To provide a central location for clinical information, scans, and tissue samples from patients with DIPG/DMG enrolled in the registry.
  • To collect tissue samples in order to study how DIPG/DMG works on the molecular level. Researchers may use the tissue samples to study molecules such as proteins and DNA. Proteins are needed for the body to function properly and DNA is the molecule that carries our genetic information. Other researchers will be able to use the stored samples in the future to learn more about DIPG/DMG. The information researchers get from the research studies will be kept in the registry along with the clinical information.
  • To help investigators around the world to work together to make more consistent diagnosis and better design of future research studies. We hope this will lead to better treatments for DIPG/DMG in the future.

Conditions

Diffuse Intrinsic Pontine Glioma

Diffuse Midline Glioma, H3 K27M-Mutant

Diffuse Midline Glioma

Study ID

NCT03101813

Start date

Jun, 2012

Status verified date

Oct, 2025

Completion date

Jun, 2047

Anticipated

Primary completion date

Jun, 2037

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • All patients of any age (living or deceased) with a diagnosis (either current or past) of a DIPG/DMG tumor
  • Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent.

Study Design

Enrollment

1500 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Identify the biological factors contributing to DIPG/DMG [ Time Frame: Through study completion, anticipated to be 25 years ]

Central Contacts and Locations

Central contacts

DIPG/DMG Operations Team

1-877-349-8074referrals@dipgregistry.org

Locations

Cincinnati Children's Hospital Medical Center

Recruiting

Cincinnati, Ohio, United States, 45229

Contacts

Courtney Blank

877-349-8074referrals@dipgregistry.org

More Information

Sponsor

Children's Hospital Medical Center, Cincinnati

Last update posted

Oct 20, 2025

Last verified

Oct, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Children's Hospital Medical Center, Cincinnati on 2025-10-20.